At the same time, G6PD overexpression was found to be associated with an increase in mTORC1 activity in blood tumors such as acute myeloid leukemia, and also predicts a poor prognosis (Poulain et al., 2017). Here, G6PD is linked to hematopoietic and lymphoid system neoplasm.